BLOG/🇮🇳India··daily

India Merger Acquisition MCA Regulatory Filings — March 29, 2026

India MCA Merger & Acquisition Tracker

7 medium priority7 total filings analysed

Executive Summary

The India MCA Merger & Acquisition Tracker reveals intense consolidation activity, dominated by EPL Limited's transformative scheme of amalgamation with Indovida India Private Limited across 5/7 filings, doubling proforma CY25 revenue to ₹8,377 Cr from EPL's standalone ₹4,568 Cr while boosting EBITDA margin to 20.9% and ROCE by 220+ bps to 20.9%. CMS Info Systems' ₹115 Cr tuck-in acquisition of FSS's ATM business expands its portfolio by ~25% to 39,000 units, aligning with 11% CAGR guidance through FY30. Healthcare Global's minor SPA/SHA amendment extends its Vizag Hospital acquisition timeline by 3 weeks. Key trends include promoter stake surges (EPL from 25.97% to 68.37%), margin accretion (+120 bps EBIT), low post-merger leverage (0.25x net debt/EBITDA), and $35-50M synergies, signaling bullish packaging and financial services M&A. Public shareholding dilution to 31.63% in EPL poses near-term overhang, but geographical diversification across 111 countries and emerging market revenue (75%) underpin long-term growth. Portfolio-level pattern: 6/7 filings positive/neutral sentiment, with EPL at 70% valuation premium reflecting market optimism amid pending NCLT/SEBI/CCI approvals.

Tracking the trend? Catch up on the prior India Merger Acquisition MCA Regulatory Filings digest from March 26, 2026.

Investment Signals(12)

  • EPL Limited↓(BULLISH)
    ▲

    Proforma CY25 revenue doubles to ₹83,767M from standalone ₹45,680M, with 20.9% EBITDA margin and EBIT accretion of 120+ bps to 13.6%

  • EPL Limited↓(BULLISH)
    ▲

    ROCE accretive by 220+ bps to 20.9% post-merger, net debt/EBITDA improves to 0.25x, synergies of $35-50M identified

  • EPL Limited↓(BULLISH)
    ▲

    Combined turnover ₹8,377 Cr (EPL ₹4,568 Cr + Indovida ₹3,809 Cr), 75% merged revenue from emerging markets vs EPL's prior base

  • CMS Info Systems↓(BULLISH)
    ▲

    ATM managed services portfolio expands ~25% from 31,000 to 39,000 units via ₹115 Cr acquisition, FY25 services revenue ₹1,300 Cr with 11% CAGR to FY30

  • EPL Limited↓(BULLISH)
    ▲

    Post-merger global footprint to 211 sites across 111 countries, enhancing geographical diversification and operational efficiencies

  • EPL Limited↓(BULLISH)
    ▲

    Share exchange ratio 286:10,000 backed by independent valuations and fairness opinion, at arm's length per SEBI merchant banker

  • CMS Info Systems↓(BULLISH)
    ▲

    Acquisition aligns with Sept 2025 Analyst Day consolidation strategy, adds 8,000 units and customer contracts from FSS (est. 1991)

  • EPL Limited↓(BULLISH)
    ▲

    Indovida net-worth ₹6,459 Cr accretes to EPL's ₹1,717 Cr base, promoter conviction via IVL 51.8% and Blackstone 16.6% post-merger stakes

  • Healthcare Global↓(BULLISH)
    ▲

    SPA/SHA amendment enables 34% additional stake acquisition in Vizag Hospital, maintaining deal momentum post-Oct 2024 first closing

  • EPL Limited↓(BULLISH)
    ▲

    70% premium valuation at ₹339/share reflects market pricing of synergies and scale, vs March 27, 2026 closing price

  • CMS Info Systems↓(BULLISH)
    ▲

    Pan-India network covers 97% districts, acquisition strengthens platform vs peers with lower geographic reach

  • EPL Limited↓(BULLISH)
    ▲

    Positive sentiment in 4/5 filings, mixed in one due to dilution but offset by strategic product range expansion

Risk Flags(10)

  • EPL Limited/Dilution↓[HIGH RISK]
    ▼

    Public shareholding dilutes sharply from 74.03% to 31.63% on fully diluted basis post-merger

  • EPL Limited/Regulatory↓[MEDIUM RISK]
    ▼

    Merger subject to NCLT, SEBI, CCI, stock exchanges, shareholder/creditor approvals; delays could pressure stock

  • EPL Limited/Governance↓[MEDIUM RISK]
    ▼

    Post-merger board rights give IVL 3+ directors, Epsilon 1; reserved matters need dual approval, potential control dilution

  • EPL Limited/Valuation↓[HIGH RISK]
    ▼

    EPL shares at 70% premium to March 27, 2026 close (₹339/share), vulnerable to approval setbacks or synergy misses

  • Healthcare Global/Timeline↓[LOW-MEDIUM RISK]
    ▼

    Second closing extended 3 weeks beyond original 18 months from Oct 2, 2024 first closing, signaling integration delays

  • EPL Limited/Shareholding Shift↓[MEDIUM RISK]
    ▼

    Promoter/promoter group surges to 68.37% from 25.97%, reducing free float and liquidity

  • CMS Info Systems/Execution↓[LOW RISK]
    ▼

    Q1 FY27 close for ₹115 Cr deal involves asset transfer and contract novation; client retention risk post-FSS transition

  • EPL Limited/Sentiment↓[MEDIUM RISK]
    ▼

    Mixed sentiment in one filing due to public dilution and reserved matters requiring IVL/Epsilon approvals

  • Healthcare Global/Deal Progress↓[LOW RISK]
    ▼

    No material SPA/SHA changes beyond timeline extension, but ongoing acquisition flags potential unresolved issues

  • EPL Limited/Scale Integration↓[MEDIUM RISK]
    ▼

    Doubling revenue to ₹8,377 Cr proforma introduces execution risks in synergies ($35-50M) and efficiencies

Opportunities(10)

Sector Themes(6)

  • Packaging Consolidation(BULLISH THEME)
    ◆

    5/7 filings on EPL-Indovida merger doubles revenue to ₹8,377 Cr, +120 bps EBIT margins; signals aggressive scale via promoter-led amalgamations, implications for 20%+ ROCE peers

  • Promoter Stake Surge(NEUTRAL THEME)
    ◆

    EPL promoters to 68.37% from 25.97%, public to 31.63%; trend of control consolidation in M&A (IVL 51.8%, Blackstone 16.6%), reduces volatility but caps upside liquidity

  • Margin & Leverage Improvement(BULLISH THEME)
    ◆

    EPL proforma 20.9% EBITDA, 0.25x net debt/EBITDA vs standalone; accretive deals dominate (vs HCG neutral), favoring low-debt acquirers in capex-heavy sectors

  • Tuck-in vs Transformational M&A(BULLISH THEME)
    ◆

    CMS ₹115 Cr (+25% units) vs EPL scale-doubling; small deals (9/10 materiality) offer quick wins, large ones (10/10) drive re-ratings post-approvals

  • Regulatory Hurdles Uniform(CAUTION THEME)
    ◆

    All key deals (EPL NCLT/SEBI/CCI, CMS Q1 FY27 close) pending multi-approvals; 2026 M&A wave risks delays but setups catalysts on clearances

  • Emerging Markets Focus(BULLISH THEME)
    ◆

    EPL 75% post-merger revenue from EMs, global 111-country footprint; cross-sector (packaging/financials) pivot to high-growth regions amid India consolidation

Watch List(8)

Filing Analyses(7)
EPL LimitedMerger/Acquisitionpositivemateriality 10/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company, increasing promoter/promoter group shareholding from 25.97% (84,479,781 shares) to 68.37% (348,701,552 shares) on a fully diluted basis, while diluting public stake from 74.03% to 31.63%. The merger, based on a share exchange ratio of 286 EPL equity shares (FV ₹2) for every 10,000 Indovida shares (FV ₹10) and supported by independent valuations and fairness opinion, aims to deliver synergies, geographical diversification, and operational efficiencies. As of Dec 31, 2025, EPL reported turnover of ₹4,568 Cr and net-worth of ₹1,717 Cr, while Indovida reported ₹3,809 Cr turnover and ₹6,459 Cr net-worth.

  • ·Share exchange ratio: 286 fully paid-up equity shares of EPL (FV ₹2 each) for every 10,000 fully paid-up equity shares of Indovida India (FV ₹10 each).
  • ·Merger subject to approvals from Stock Exchanges, SEBI, NCLT, CCI, shareholders, and creditors.
  • ·IVL to nominate at least 3 directors, Epsilon 1 director on EPL Board post-merger; certain reserved matters require prior approval of both.
  • ·Board meeting held on March 29, 2026 from 5:00 P.M. to 5:25 P.M. IST.
  • ·Valuation reports dated March 28, 2026 by independent valuers; fairness opinion by SEBI-registered merchant banker.
EPL LimitedMerger/Acquisitionpositivemateriality 10/10

29-03-2026

EPL Limited announces the Scheme of Amalgamation with Indovida India Private Limited, creating a merged entity with INR 83,767 million revenue (CY25 proforma), 20.9% EBITDA margin, and net debt/EBITDA of 0.25x, doubling scale from EPL's standalone INR 45,680 million. The merger is EBIT margin accretive (120+ bps to 13.6%) and ROCE accretive (220+ bps to 20.9%), with identified synergies of $35-50 million, though EPL's valuation at INR 339 per share reflects a 70% premium to the March 27, 2026 closing price. Approximately 75% of merged revenue from emerging markets supports growth potential amid stable profitability metrics.

  • ·Post-merger shareholding: Indorama Ventures 51.8%, Blackstone 16.6%, Public 31.6%
  • ·EPL global footprint: 211 manufacturing sites across 111 countries
  • ·Indovida 100% owned by Indorama Ventures Netherlands B V
  • ·Merged entity market positions leading in laminated tubes (EPL) and rigid PET (Indovida) across key emerging markets including Philippines, Vietnam, Nigeria, Egypt, Myanmar, Thailand, Tanzania, Ghana
  • ·Sustainability: EPL 90% recyclable tubes capacity, 21% renewable energy; Indovida 100% recyclable PET resin capacity, 150kMT rPET consumption goal by 2035
EPL LimitedMerger/Acquisitionmixedmateriality 9/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company, supported by a joint valuation and fairness opinion, aiming for synergies in packaging products, geographical diversification, and operational efficiencies with combined turnover of ₹8,377 Cr (Jan-Dec 2025). Post-merger, promoter/promoter group shareholding surges to 68.37% from 25.97% on a fully diluted basis, significantly diluting public holding to 31.63% from 74.03%. The merger, along with MIA, SHA, and TSA executions, remains subject to approvals from NCLT, CCI, SEBI, stock exchanges, and shareholders/creditors.

  • ·Share exchange ratio: 286 fully paid-up equity shares of EPL (FV ₹2 each) for every 10,000 fully paid-up equity shares of Indovida India (FV ₹10 each).
  • ·IVL to nominate at least 3 directors; Epsilon to nominate 1 director on EPL Board post-merger.
  • ·Company requires prior approval from Epsilon and IVL for certain reserved matters post-SHA.
  • ·Approvals required: Stock Exchanges, SEBI, NCLT, CCI, shareholders and creditors.
  • ·Board meeting: Mar 29, 2026, 5:00-5:25 PM IST.
  • ·Valuation reports and fairness opinion dated Mar 28, 2026.
CMS Info Systems LimitedMerger/Acquisitionpositivemateriality 9/10

29-03-2026

CMS Info Systems Limited announced the acquisition of Financial Software and Systems Private Limited (FSS)'s ATM Managed Services business for a purchase consideration of up to ₹115 crores, adding ~8,000 units and expanding the managed services portfolio from ~31,000 to ~39,000 units. This transaction strengthens the ATM Management Solutions platform, which generated ~₹1,300 crores in FY25 services revenue with an 11% CAGR outlook through FY30, and is expected to close in Q1 FY27. The deal aligns with CMS's publicly stated consolidation strategy outlined at its September 2025 Analyst Day.

  • ·FSS established in 1991 with public and private sector banking clients
  • ·CMS's pan-India network spans 97% of districts
  • ·Transaction involves transfer of operating assets and novation of customer contracts
Healthcare Global Enterprises LimitedMerger/Acquisitionneutralmateriality 4/10

29-03-2026

HealthCare Global Enterprises Limited executed second amendment agreements to the Share Purchase Agreement (SPA) and Shareholders Agreement (SHA) dated March 29, 2026, for the ongoing acquisition of Vizag Hospital and Cancer Research Centre Private Limited. The amendments extend the Second Closing Date by 3 weeks beyond the original 18 months from the First Closing Date of October 02, 2024, allowing the Company to acquire an additional 34% equity share capital. No other material changes were made to the SPA or SHA.

  • ·First Closing Date: October 02, 2024
  • ·Original Second Closing timeline: within 18 months of First Closing Date
  • ·Extension period: 3 weeks
  • ·Stock Codes: BSE – 539787, NSE – HCG
  • ·Disclosure reference: Regulation 30(2) and (6) read with Schedule III Part A Para A sub-para (1) of SEBI LODR Regulations, 2015 and SEBI Circular dated July 13, 2023
EPL LimitedMerger/Acquisitionpositivemateriality 9/10

29-03-2026

EPL Limited's Board approved the scheme of amalgamation merging Indovida India Private Limited into the Company on a going concern basis, with a share exchange ratio of 286 EPL equity shares (FV ₹2) for every 10,000 Indovida shares (FV ₹10), subject to approvals from NCLT, SEBI, CCI, stock exchanges, and shareholders/creditors. The merger is expected to deliver synergies including wider product range, cost savings, geographical diversification, and enhanced efficiencies in the packaging sector. Post-merger, promoter/promoter group shareholding will increase from 25.97% to 68.37% on a fully diluted basis.

  • ·IVL holds 99.99% of Indovida India and 24.44% in EPL; Epsilon holds 25.97% in EPL.
  • ·Merger at arm's length basis per independent valuers' report (Mar 28, 2026) and SEBI-registered merchant banker's fairness opinion.
  • ·Post-merger board rights: Epsilon nominates 1 director, IVL nominates at least 3; certain reserved matters require prior approval of both.
  • ·Approvals required: Stock Exchanges, SEBI, NCLT, CCI, requisite shareholders/creditors.
  • ·Board meeting: Mar 29, 2026, 5:00 P.M. to 5:25 P.M. IST.
EPL LimitedMerger/Acquisitionneutralmateriality 9/10

29-03-2026

EPL Limited's Board of Directors approved the Scheme of Amalgamation of Indovida India Private Limited (Transferor Company) with EPL Limited (Transferee Company) on March 29, 2026. The company has scheduled an investors' and analysts' conference call on March 30, 2026, at 11:00 AM IST to discuss the scheme, with participation from MD & Global CEO Hemant Bakshi, COO M.R. Ramasamy, CFO Deepak Goyal, and Head Legal Onkar Ghangurde. No financial details or performance metrics were disclosed in this intimation.

  • ·ISIN: INE255A01020
  • ·Scrip Code: 500135
  • ·Trading Symbol: EPL
  • ·Conference call dial-in: Primary +91 22 6280 1297, Secondary +91 22 7115 8198
  • ·Toll-free numbers: USA 1 866 746 2133, UK 0 808 101 1573, Singapore 800 101 2045, Hong Kong 800 964 448
  • ·Diamond Pass: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=4568962&linkSecurityString=2527b7a15e

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 7 filings

Subscribe nowBrowse all digests

🇮🇳 More from India

View all →

March 26, 2026

India Pre-Market Regulatory Roundup — March 26, 2026

India Pre-Market Regulatory Roundup

March 26, 2026

India Quarterly Results BSE NSE Announcements — March 26, 2026

India Quarterly Results BSE NSE Announcements

March 26, 2026

India Upcoming Corporate Actions BSE NSE — March 26, 2026

India Upcoming Corporate Actions BSE NSE

March 26, 2026

India MCA Insolvency Liquidation Filings — March 26, 2026

India MCA Insolvency Liquidation Filings

← All India digests
India Merger Acquisition MCA Regulatory Filings — March 29, 2026 | Gunpowder Blog